IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H)
J. Clin. Invest. 119:7 doi:10.1172/JCI37878 [Go to this article.]

Figure 3
Caspase-3 expression pretreatment and 9 months after alemtuzumab.

CASP3 mRNA expression relative to ACTB mRNA expression in (A) CD3⁺ T cells, (B) CD14⁺ monocytes, and (C) CD19⁺ B cells, either immediately ex vivo or following stimulation with MBP or polyclonal stimulation (anti-CD3/28 antibodies) (*P < 0.05). Box-and-whisker plots used depict the smallest value, lower quartile, median, upper quartile, and largest value.